A phase 3, open-label, extension study of S-6810 in patients with mycosis fungoides or Sezary syndrome

Trial Profile

A phase 3, open-label, extension study of S-6810 in patients with mycosis fungoides or Sezary syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Interferon gamma-1a (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions
  • Sponsors Shionogi
  • Most Recent Events

    • 07 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top